

ESPI REPORT NO. 8/2026 | 9 March 2026 | Update of objectives for the BACTEROMIC project for 2026-2027

Legal basis: Article 17(1) of the MAR Regulation – inside information

Further to the adoption of objectives as part of the implementation of the Scope Fluidics Group Strategy until 2027, the Management Board of Scope Fluidics S.A. (“**Scope**”) announces the adoption of an update of objectives for the BACTEROMIC project for the years 2026–2027 (the “**Objectives**”), carried out by Bacteromic sp. z o.o. (“**Bacteromic**”) – a wholly-owned subsidiary of Scope.

Taking into account the information obtained in recent months by the Bacteromic team regarding the preferences of end users of automated antimicrobial susceptibility testing (AST) diagnostic systems, as well as the plan adopted in February 2026 to achieve readiness of the production line for BACTEROMIC system panels, on 12 February 2026 the Bacteromic team recommended to the Management Board that the objectives for the BACTEROMIC project for the years 2026–2027 be updated. The Management Board analyzed this recommendation, which was subsequently presented to the Supervisory Board. The Management Board approved the Objectives on 5 March 2026, and the Supervisory Board approved them on 9 March 2026. A description of the Objectives constitutes an attachment to this report. The disclosure to the public of information regarding the Objectives was delayed on 12 February 2026.